Search Results



Your search for Matthew Stenger matches 106 pages

Showing 1 - 50


gynecologic cancers

Final Efficacy Analysis of 9-Valent Human Papillomavirus Vaccine Trial

The final efficacy analysis of a trial of 9-valent human papillomavirus (HPV) vaccine has shown a high preventive effect against disease due to the additional HPV pathogenic strains covered compared with the quadrivalent vaccine at up to 6 years. These findings were reported by Huh et al in The...

gynecologic cancers

Final Overall Survival Results of GOG 240 Trial Adding Bevacizumab to Chemotherapy in Advanced Cervical Cancer

As reported in The Lancet by Tewari et al, the final overall survival results of the phase III Gynecologic Oncology Group (GOG) 240 trial show continued benefit of the addition of bevacizumab (Avastin) to chemotherapy in patients with metastatic, persistent, or recurrent cervical carcinoma. Study...

gynecologic cancers

Olaparib Tablets as Maintenance in BRCA1/2-Mutant Platinum-Sensitive Relapsed Ovarian Cancer

A phase III trial (SOLO2/ENGOT-Ov21) has shown improved progression-free survival with an olaparib tablet formulation vs placebo as maintenance therapy in patients with BRCA1/2-mutant platinum-sensitive relapsed ovarian cancer. These study results were reported by Pujade-Lauraine et al in The...

gynecologic cancers

Dutch Study Assesses Long-Term Risk of HPV-Related Carcinoma and Premalignancies After CIN3 Diagnosis

A Dutch study has shown long-lasting risk for human papillomavirus (HPV)-related carcinoma and premalignancies in women with a diagnosis of cervical intraepithelial neoplasia grade 3 (CIN3). The findings were reported by Ebisch et al in the Journal of Clinical Oncology. Study Details The...

gynecologic cancers

Tumor Microvessel Density and Outcome With Bevacizumab in Ovarian Cancer

A retrospective biomarker analysis of the phase III GOG-0218 trial indicated a higher tumor microvessel density was associated with progression-free and overall survival benefit with bevacizumab (Avastin) vs placebo plus front-line chemotherapy in patients with ovarian cancer. These findings were...

gynecologic cancers

Pembrolizumab in Advanced PD-L1–Positive Endometrial Cancer

Pembrolizumab (Keytruda) showed activity in previously treated patients with advanced programmed cell death ligand 1 (PD-L1)–positive endometrial cancer in a cohort of the phase Ib KEYNOTE-028 study. These findings were reported in the Journal of Clinical Oncology by Ott et al. Study Details ...

gynecologic cancers

Durvalumab With Olaparib or Cediranib in Women’s Cancers

As reported in the Journal of Clinical Oncology by Lee et al, a phase I study has shown activity of the combination of the programmed cell death ligand 1 (PD-L1) inhibitor durvalumab with either the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza) or vascular endothelial growth...

gynecologic cancers

Adding Bevacizumab to Paclitaxel-Carboplatin in Recurrent Platinum-Sensitive Ovarian Cancer

In a phase III trial (NRG Oncology/Gynecologic Oncology Group GOG-0213 trial) reported in The Lancet Oncology, Coleman et al found evidence of an overall survival advantage with the addition of bevacizumab (Avastin) to paclitaxel-carboplatin in recurrent platinum-sensitive ovarian cancer. The...

gynecologic cancers

Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy for Stage I Endometrial Cancer

A multinational equivalence trial has shown no difference in disease-free survival with total laparoscopic hysterectomy vs total abdominal hysterectomy in women with treatment-naive stage I endometrial cancer. The findings were reported by Janda et al in JAMA. Study Details In the trial, 760...

gynecologic cancers

Evidence of Stage Shift in Ovarian Cancer Detected in UK Screening Study

As reported in the Journal of Clinical Oncology, Rosenthal et al found evidence of a shift to an earlier stage among ovarian cancers detected in high-risk women in the UK Familial Ovarian Cancer Screening Study. Study Details The study was performed to evaluate performance of screening using...

gynecologic cancers

Hormone Maintenance Therapy in Low-Grade Serous Cancer of the Ovary or Peritoneum

In a single-institution experience reported in the Journal of Clinical Oncology, Gershenson et al at MD Anderson Cancer Center found that hormonal maintenance therapy was associated with improved progression-free survival among women with stage II to IV low-grade serous carcinoma of the ovary or...

gynecologic cancers

Comparison of Sentinel Lymph Node Biopsy vs Lymphadenectomy in Endometrial Cancer Staging

In the FIRES prospective cohort study reported in The Lancet Oncology, Rossi et al found that sentinel lymph node mapping was highly accurate in detecting metastases compared with complete lymphadenectomy in women with endometrial cancer. Study Details The study included women with clinical stage ...

gynecologic cancers

Is Mirvetuximab Soravtansine Active in Platinum-Resistant Ovarian Cancer?

Moore et al found that mirvetuximab soravtansine (also known as IMGN853)—an antibody-drug conjugate targeting folate receptor alpha (FRα)—is active in FRα-positive platinum-resistant ovarian cancer, according to a phase I expansion cohort study reported in the Journal of...

gynecologic cancers

Diagnostic Laparoscopy May Predict Result of Primary Cytoreductive Surgery in Suspected Advanced Ovarian Cancer

In a Dutch trial reported in the Journal of Clinical Oncology, Rutten et al found that initial diagnostic laparoscopy can prevent futile primary cytoreductive surgery in patients with suspected advanced-stage ovarian cancer. Study Details In the trial, 201 women who were qualified for primary...

gynecologic cancers

Rucaparib Appears Effective in Relapsed Platinum-Sensitive High-Grade Ovarian Carcinoma

In part 1 of the phase II ARIEL2 trial reported in The Lancet Oncology, Swisher et al found that the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib was associated with prolonged progression-free survival among patients with relapsed platinum-sensitive high-grade ovarian carcinoma who had...

gynecologic cancers

No Advantage to Adding Seribantumab to Paclitaxel in Platinum-Resistant/Refractory Ovarian Cancer, but Subgroup May Benefit

In a phase II study reported in the Journal of Clinical Oncology, Liu et al found no progression-free survival benefit of adding the anti-HER3 (ErbB3) antibody seribantumab to paclitaxel in unselected patients with advanced platinum-resistant or -refractory ovarian cancer. However, exploratory...

gynecologic cancers

Study Finds Niraparib Maintenance Improves Progression-Free Survival in Platinum-Sensitive Recurrent Ovarian Cancer

In a phase III trial reported at the recent European Society for Medical Oncology Congress and in The New England Journal of Medicine by Mirza et al, maintenance therapy with the PARP (poly ADP ribose polymerase) 1/2 inhibitor niraparib significantly prolonged progression-free survival vs placebo...

gynecologic cancers

Survival Benefit Reported With Maintenance Olaparib in Platinum-Sensitive Recurrent Serous Ovarian Cancer With BRCA Mutation

Maintenance olaparib (Lynparza) appeared to be associated with an overall survival benefit vs placebo in women with platinum-sensitive serous ovarian cancer and BRCA1 and BRCA2 mutations, according to an updated analysis of a phase II trial reported in The Lancet Oncology by Ledermann et al....

breast cancer
gynecologic cancers

Study Suggests Role of Bilateral Oophorectomy in Preventing Premenopausal Breast Cancer in BRCA2- but Not BRCA1-Mutation Carriers

Bilateral oophorectomy was associated with prevention of premenopausal breast cancer in BRCA2- but not BRCA1-mutation carriers, according to a study reported by Kotsopoulos et al in the Journal of the National Cancer Institute. The study included 3,722 women with BRCA mutations in a prospective...

gynecologic cancers

Shorter Survival Reported With Neoadjuvant Chemotherapy vs Primary Reductive Surgery in Stage IIIC Ovarian Cancer

Neoadjuvant chemotherapy was associated with shorter survival vs primary cytoreductive surgery in patients with stage IIIC ovarian cancer, according to a multi-institute observational study reported by Meyer et al in the Journal of Clinical Oncology. The study involved 1,538 women with stage IIIC...

gynecologic cancers

Study Finds HIV Infection Linked to Reduced Survival Among Women With Cervical Cancer in Botswana

Despite access to and use of antiretroviral therapy, HIV (human immunodeficiency virus) infection was associated with reduced survival in women with cervical cancer in Botswana, according to a study reported by Dryden-Peterson et al in the Journal of Clinical Oncology. Study Details The study...

gynecologic cancers

Predicted Burden of Cervical Cancer With vs Without Effective Screening in Baltic, Central, and Eastern European Countries

Vaccarella et al estimated changes in the incidence of cervical cancer through 2040 in six Baltic, central, and eastern European (BCEE) countries on the hypotheses of continued absence of effective screening programs vs progressive implementation of such programs. Their findings were reported in...

gynecologic cancers

ASCO and SGO Release Clinical Practice Guideline on Neoadjuvant Therapy for Newly Diagnosed Advanced Ovarian Cancer

As reported by Alexi A. Wright, MD, MPH, of Dana-Farber Cancer Institute, and colleagues in the Journal of Clinical Oncology, ASCO and the Society of Gynecologic Oncology (SGO) have released a clinical practice guideline on neoadjuvant therapy for patients with newly diagnosed stage IIIC or IV...

gynecologic cancers

Recommendations for Surveillance of Premature Ovarian Insufficiency in Female Survivors of CAYA Cancers

Harmonized recommendations for surveillance of premature ovarian insufficiency in female survivors of childhood, adolescent, and young adult (CAYA) cancers have been published by van Dorp et al in the Journal of Clinical Oncology on behalf of the International Late Effects of Childhood Cancer...

gynecologic cancers

Potential Increased Risk of Serous/Serous-like Endometrial Carcinoma After RRSO in Women With BRCA1 Mutation

In a prospective cohort study reported in JAMA Oncology, Shu et al found that risk for serous/serous-like endometrial carcinoma appeared to be increased after risk-reducing salpingo-oophorectomy (RRSO) without hysterectomy in women harboring the BRCA1 mutation. The overall risk of uterine cancer...

gynecologic cancers

No Overall Advantage to Adding Pertuzumab to Chemotherapy in Platinum-Resistant Ovarian Cancer, but Subgroup May Benefit

According to the European phase III PENELOPE trial reported in the Journal of Clinical Oncology, Kurzeder et al found that adding pertuzumab (Perjeta) to investigator’s choice of chemotherapy did not improve progression-free survival in women with low-HER3 mRNA–expressing...

solid tumors
gynecologic cancers

Study Finds Apparent Benefit of Adding Fosbretabulin to Bevacizumab in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma

Adding the vascular-disrupting agent fosbretabulin to bevacizumab (Avastin) improved outcomes in patients with recurrent ovarian, tubal, or peritoneal carcinoma, according to a randomized phase II NRG Oncology/Gynecologic Oncology Group study reported in the Journal of Clinical Oncology by Monk et...

gynecologic cancers
issues in oncology

ASCO Statement on Human Papillomavirus Vaccination for Cancer Prevention

As reported in the Journal of Clinical Oncology by Bailey et al, ASCO has released a statement on increasing human papillomavirus (HPV) vaccination to prevent HPV-related cancers in the United States. In the United States, HPV is estimated to cause approximately 99.7% of cervical cancers, 60% of...

gynecologic cancers

Study Reports No Overall Benefit of Adding Farletuzumab to Chemotherapy in Relapsed Ovarian Cancer, but Potential Subgroup Benefit Identified

Addition of the antifolate receptor-α antibody farletuzumab to carboplatin/taxane did not improve progression-free survival in patients with ovarian cancer in first platinum-sensitive relapse, reported Vergote et al in the Journal of Clinical Oncology. However, benefit was observed in...

gynecologic cancers

Adding Cediranib to Platinum Therapy Increases Progression-Free Survival in Relapsed Platinum-Sensitive Ovarian Cancer

The phase III ICON6 trial showed that adding cediranib to platinum-based therapy increased progression-free survival and toxicity in women with first relapse of platinum-sensitive ovarian cancer, reported Ledermann et al in The Lancet. Study Details In the double-blind trial, 456 women with...

gynecologic cancers
supportive care
symptom management

Fosaprepitant Combination Reduces Risk of Emesis During Chemoradiotherapy for Cervical Cancer

The addition of fosaprepitant (Emend) to palonosetron and dexamethasone reduced the risk of emesis during 5 weeks of chemoradiotherapy for cervical cancer, according to the phase III GAND-emesis trial reported in The Lancet Oncology by Ruhlmann et al. Study Details In the double-blind trial, 234...

gynecologic cancers

Frequent Copy Number Gain of Genes for PD-1 Ligands in Squamous Cell Carcinoma of the Cervix or Vulva

In a study reported in JAMA Oncology, Howitt et al identified copy number gain of genes encoding programmed cell death protein 1 (PD-1) ligands in a sizable proportion of patients with squamous cell carcinoma of the cervix or vulva. Study Details The study involved fluorescence in situ...

gynecologic cancers

Study Finds No Progression-Free Survival Benefit for Weekly Dose-Dense vs Every-3-Week Paclitaxel Plus Carboplatin in Ovarian Cancer

Weekly dose-dense paclitaxel did not provide a progression-free survival benefit over every-3-week paclitaxel in combination with carboplatin and with or without elective bevacizumab (Avastin) in patients with previously untreated ovarian cancer, according to the results of the phase III GOG-0262...

gynecologic cancers

Study Finds No Adverse Impact of Minimally Invasive Hysterectomy on Long-Term Survival in Endometrial Cancer

Use of minimally invasive hysterectomy did not seem to have an adverse impact on long-term survival in women with endometrial cancer, according to an analysis reported in the Journal of Clinical Oncology by Wright et al. Study Details The study involved Surveillance, Epidemiology, and End Result...

gynecologic cancers
issues in oncology

UK Study Suggests Potential Mortality Benefit of Ovarian Cancer Screening in Postmenopausal Women

As reported in The Lancet by Jacobs et al, the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) suggests there may be a mortality benefit of ovarian cancer screening in postmenopausal women. Study Details In the trial, 202,546 postmenopausal women aged 50 to 74 years from 13 centers...

gynecologic cancers
gynecologic cancers
issues in oncology

Study Shows ACA Coverage Expansion Resulted in Increased Cervical Cancer Diagnosis at Early Stage in Young Women

In a study reported in a research letter in JAMA, Robbins et al found evidence that the Affordable Care Act Dependent Coverage Expansion (ACA-DCE) has resulted in increased diagnosis of cervical cancer at an early stage and increased use of fertility-sparing treatments in women aged 21 to 25 years. ...

gynecologic cancers
gynecologic cancers

European Trial Shows Front-Line Addition of Nintedanib to Standard Chemotherapy Improves Progression-Free Survival in Advanced Ovarian Cancer

In a European phase III trial (AGO-OVAR 12) reported in The Lancet Oncology, du Bois et al found that adding the antiangiogenic multikinase inhibitor nintedanib (Ofev) to carboplatin/paclitaxel improved progression-free survival in patients with newly diagnosed ovarian cancer. Gastrointestinal...

gynecologic cancers

Addition of Cediranib to Carboplatin/Paclitaxel Improves Progression-Free Survival in Metastatic/Recurrent Cervical Cancer in UK Phase II Trial

In a UK phase II trial reported in The Lancet Oncology, Symonds et al found that the addition of the investigational VEGFR1, -2, and -3 inhibitor cediranib to carboplatin/paclitaxel improved progression-free survival in patients with metastatic or relapsed cervical cancer. The addition of cediranib ...

gynecologic cancers
gynecologic cancers

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer

Results of the phase III AHT trial reported in the Journal of Clinical Oncology by Eeles et al suggest that adjuvant hormonal therapy may improve survival in women with epithelial ovarian cancer. The trial, started in 1990, was stopped early due to low recruitment. Study Details In the open-label ...

gynecologic cancers
gynecologic cancers

Therapeutic HPV-16/18 Vaccine Produces Regression of Cervical Intraepithelial Neoplasia Grade 2/3 in Phase II Trial

In a phase IIb trial reported in The Lancet, Trimble et al found that a therapeutic synthetic vaccine (VGX-3100) targeting human papillomavirus (HPV) 16 and 18 E6 and E7 proteins increased the frequency of regression of HPV-16/18–related cervical intraepithelial neoplasia grade 2/3 vs...

gynecologic cancers

Co-infection With High-Risk and Low-Risk HPV Reduces Risk of Squamous Cervical Cancer vs High-Risk HPV Alone

In a study reported in the Journal of the National Cancer Institute, Sundström et al found that women co-infected with high-risk and low-risk human papillomavirus (HPV) had reduced risk of squamous cervical cancer (SCC), but not cancer in situ (CIS) compared with women with high-risk HPV...

issues in oncology
gynecologic cancers
issues in oncology

Study Explores Link Between MAPK Pathway Alteration and Long-Term Response to MEK Inhibitor in Serous Ovarian Cancer

In a study reported in the Journal of Clinical Oncology, Grisham et al identified a novel alteration in the MAP2K1 gene encoding for MEK1 that appeared to explain a complete response ongoing for more than 5 years in a patient treated with the MEK inhibitor selumetinib for metastatic low-grade...

gynecologic cancers

Japanese Phase II Trial Shows Activity of Nivolumab in Platinum-Resistant Ovarian Cancer

In a Japanese phase II trial reported in the Journal of Clinical Oncology, Hamanishi et al found that the anti–PD-1 (programmed cell death protein 1) antibody nivolumab (Opdivo) was active in patients with relapsed or advanced platinum-resistant ovarian cancer. Study Details In the study,...

gynecologic cancers
issues in oncology

Analysis Indicates That Tubal Ligation Is Associated With Lower Endometrial Cancer Stage at Diagnosis and Improved Survival

In an analysis from the NRG Oncology/Gynecologic Oncology Group 210 trial reported in the Journal of the National Cancer Institute, Felix et al found that tubal ligation, which should impede transtubal passage of cells, was associated with lower stage of endometrial cancer at presentation and...

gynecologic cancers

POLE-Mutant and Microsatellite-Unstable Endometrial Tumors May Be Candidates for Anti–PD-1 Treatment

In a study reported in JAMA Oncology, Howitt et al found that polymerase e (POLE)-mutant and microsatellite-unstable endometrial tumors may be candidates for anti–PD-1 (programmed cell death protein 1) immunotherapy. Study Details In the study, neoantigen load was predicted on the basis of...

gynecologic cancers
issues in oncology

Oral Contraceptives May Offer Long-Term Protection From Endometrial Cancer

In an individual-patient meta-analysis reported in The Lancet Oncology, the Collaborative Group on Epidemiological Studies on Endometrial Cancer found that oral contraceptive use was associated with long-term protection from endometrial cancer. Reduction in risk was greater for carcinomas than...

gynecologic cancers
gynecologic cancers

Addition of Bevacizumab to Standard Chemotherapy Does Not Improve Overall Survival in Newly Diagnosed Ovarian Cancer

Final overall survival results of the phase III ICON7 trial reported in The Lancet Oncology by Oza et al indicate no significant increase with the addition of bevacizumab (Avastin) to standard chemotherapy in women with newly diagnosed ovarian cancer. However, overall survival benefit of...

gynecologic cancers

Phase II Trial Shows Activity of mTOR Inhibitor Ridaforolimus in Advanced Endometrial Carcinoma

In a randomized phase II trial reported in the Journal of Clinical Oncology, Oza et al found that the mTOR inhibitor ridaforolimus was active in previously treated advanced endometrial carcinoma. Study Details In the open-label study, 130 patients with progressive disease after one or two lines...

gynecologic cancers
issues in oncology

Risk Algorithm Using Serial CA-125 Measurements Increases the Number of Screen-Detected Ovarian Cancers

As reported in the Journal of Clinical Oncology by Menon et al, findings in the United Kingdom Collaborative Trial of Ovarian Cancer Screening indicate that the number of screen-detected ovarian cancers is doubled by using the risk of ovarian cancer algorithm (ROCA) with serial CA-125 measurements...

gynecologic cancers
gynecologic cancers

UK Trial Shows Neoadjuvant Platinum-Based Chemotherapy Noninferior to Adjuvant Chemotherapy in Advanced Ovarian Cancer

In the UK phase III CHORUS trial reported in The Lancet, Kehoe et al found that a strategy of three cycles of platinum-based chemotherapy followed by delayed surgery and three additional cycles of chemotherapy was associated with overall survival noninferior to that achieved with surgery followed...

Advertisement



Advertisement


Advertisement